← Back to Search

Activity-based Companion Care for Dementia (MEMORI Corps Trial)

N/A
Waitlist Available
Led By Quincy Samus, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have an established physician clinical diagnosis of dementia (any stage) and confirmed with the Clinical Dementia Rating Scale of >0.5
PWD must be able to participate in >2 basic Activities of Daily Living
Must not have
PWD planned transition from home in less than 6 months
PWD at end-stage disease (e.g. bed-bound, non-communicative, or hospice)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a 12-week program delivered by older volunteers can help people with dementia and their caregivers. The volunteers will either serve in the program immediately (active duty) or after a 12-week waitlist period (control group).

Who is the study for?
This trial is for English-speaking pairs of people with dementia (PWD) and their informal caregivers (CG) living in Baltimore City or County. PWD should be diagnosed with dementia, able to do some daily activities, and not have had formal respite care recently. Caregivers must live with the PWD and assist them. Volunteers aged 55+ who pass health checks can also join.
What is being tested?
The MEMORI Corps program matches trained senior volunteers with dementia patients and caregivers for a 12-week period to provide activity-based companion care. The study compares this intervention against an augmented waitlist control group to assess its effectiveness.
What are the potential side effects?
Since this trial involves non-medical interventions like companionship and activities, there are no direct medical side effects expected from participation in the MEMORI Corps program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with dementia, confirmed by a specific test score above 0.5.
Select...
I can perform more than two basic daily activities on my own.
Select...
I am over 18 and considered a dependable caregiver.
Select...
I live with and help someone with daily activities.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I plan to move out of my home within 6 months.
Select...
I am at the end stage of my disease and cannot move or communicate effectively.
Select...
I have trouble controlling my bladder or bowels.
Select...
I have severe behavioral issues that could harm me or others.
Select...
I am unable to understand or sign the consent form.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in activity engagement as assessed by the Community Healthy Activities Model Program for Seniors activity questionnaire
Change in depressive symptoms in caregivers as assessed by The Patient Health Questionnaire (PHQ) - 8
Change in neuropsychiatric symptoms as assessed by Neuropsychiatric Inventory (NPI) score
+7 more
Secondary study objectives
Change in depressive symptoms in senior companion volunteers as assessed by The Patient Health Questionnaire (PHQ) - 8
Change in objective caregiver burden as assessed by time estimates in performing tasks
Change in self-reported balance as assessed by the Centers for Disease Control Stopping Elderly Accidents, Deaths & Injuries (CDC STEADI-3)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: ControlExperimental Treatment1 Intervention
Augmented waitlist control.
Group II: Active InterventionExperimental Treatment1 Intervention
Intervention arm with MEMORI Corps program
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEMORI Corps program
2022
N/A
~180

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,498 Total Patients Enrolled
33 Trials studying Dementia
81,563 Patients Enrolled for Dementia
Alzheimer's AssociationOTHER
99 Previous Clinical Trials
43,269 Total Patients Enrolled
38 Trials studying Dementia
33,474 Patients Enrolled for Dementia
National Institute on Aging (NIA)NIH
1,804 Previous Clinical Trials
28,194,724 Total Patients Enrolled
296 Trials studying Dementia
23,635,365 Patients Enrolled for Dementia
Quincy Samus, PhDPrincipal InvestigatorJohns Hopkins University

Media Library

MEMORI Corps program Clinical Trial Eligibility Overview. Trial Name: NCT03896711 — N/A
Dementia Research Study Groups: Active Intervention, Control
Dementia Clinical Trial 2023: MEMORI Corps program Highlights & Side Effects. Trial Name: NCT03896711 — N/A
MEMORI Corps program 2023 Treatment Timeline for Medical Study. Trial Name: NCT03896711 — N/A
~47 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top